Table 2.
CHIKV Vaccines and Therapeutics Tested in NHPs.
| Vaccine Type | Number of Vaccinations | Immunogenicity Measured | Challenge Dose/Strain/Route | Reference |
|---|---|---|---|---|
| Formalin-inactivated/UV-inactivated | 3 | Neutralizing antibodies | Not reported | [60,90] |
| Live-attenuated | 1 | Neutralizing antibodies | 105 PFU / CHIKV-15561 / i.m. | [77] |
| Virus-Like Particle (VLP) | 3 | Neutralizing antibodies | 1010 PFU / CHIKV-LR/ i.v. | [76] |
| DNA | 5 | Neutralizing antibodies / T cells | Not reported | [91] |
| CHIKV/IRES | 1 | Neutralizing antibodies | 105 PFU / CHIKV-LR / s.c. | [74] |
| Therapeutic Type | Infection Dose/Strain/Route | Therapeutic Delivery | Measure of Protection | |
| Antibody Therapeutic | 107 PFU / CHIKV-LR / s.c. | 1 & 3 dpi / i.v. | Virus dissemination | [63] |